Sole Financial Advisor to CalciMedica Inc.
On March 20th, 2023, CalciMedica Inc. (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, announced the closing of its merger with Graybug Vision, Inc. CalciMedica’s stock commenced trading on March 21st.
CalciMedica is headquartered in La Jolla, CA and its management team leads the combined company following this transaction with Rachel Leheny, Ph.D. assuming the role of chief executive officer. The combined company’s board of directors is composed of seven members, five selected by CalciMedica: Robert Wilson, Fred Middleton, Allan Shaw, Eric Roberts and Rachel Leheny, Ph.D.; and two selected by Graybug: Fred Guerard, PharmD, and Eric Bjerkholt.
The combined company will focus on developing CalciMedica’s lead product candidate Auxora™ (zegocractin), a proprietary, intravenous-formulated, small molecule calcium release-activated calcium (CRAC) channel inhibitor designed to treat life-threatening inflammatory diseases includingacute pancreatitis (AP), asparaginase-associated pancreatitis (AAP) which is a toxicity caused by asparaginase treatment for pediatric acute lymphoblastic leukemia (ALL), acute kidney injury (AKI), acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) for which there are no currently approved therapies.
This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
2023 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 5631696.1